Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arda Durmaz

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
Blood|April 13, 2023
IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuriaCarmelo Gurnari, Pedro Henrique Prata, Luiz Fernando B Catto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2022
Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal HemoglobinuriaCarmelo Gurnari, Simona Pagliuca, Pedro Henrique Prata, et al.
Leukemia|December 3, 2025
DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective studyCarmelo Gurnari, Hideki Makishima, Arda Durmaz, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
Blood|April 13, 2023
IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuriaCarmelo Gurnari, Pedro Henrique Prata, Luiz Fernando B Catto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2022
Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal HemoglobinuriaCarmelo Gurnari, Simona Pagliuca, Pedro Henrique Prata, et al.
Leukemia|December 3, 2025
DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective studyCarmelo Gurnari, Hideki Makishima, Arda Durmaz, et al.
Pageof 6